(Q53128686)

English

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

scientific article published on 11 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

1 reference

based on heuristic

inferred from title

author name string

Y Y Janjigian

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

D Werner

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

C Pauligk

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

K Steinmetz

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

D P Kelsen

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

E Jäger

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

H-M Altmannsberger

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

E Robinson

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

L J Tafe

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

L H Tang

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

M A Shah

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

S-E Al-Batran

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

publication date

11 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

23

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

2656-2662

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER 2/neu protein expression in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER-2 amplification is highly homogenous in gastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS104

21 January 2018

Identifiers

10.1093/ANNONC/MDS104

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22689179

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53128686&oldid=1242704857"